Role of Ion Channel Genes as Targets in Oncology

A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Human Genomics and Genetic Diseases".

Deadline for manuscript submissions: closed (31 December 2019) | Viewed by 2939

Special Issue Editors


E-Mail Website
Guest Editor
Intracellular Ion Channel Group, Department of Biology, Università degli Studi di Padova, Padova, Italy
Interests: mitochondria; Wnt signaling; ER-mitochondria contact sites; cancer
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Intracellular Ion Channel Group, Department of Biology, Università degli Studi di Padova, Padova, Italy
Interests: ion channels; mitochondria; electrophysiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Ion channels are a wide population inside the cell, divided into several subfamilies, and they play an important role in modulating cellular functions to determine cell fate. Importantly, recent evidence has demonstrated that the plasma membrane, as well as intracellular ion channels, are involved in cancer progression and the acquisition of the main features of the cancer cells, such as metabolic re-programming, absence of proliferative control, resistance to cell death induction, stimulation of angiogenesis, migration, and invasion. Notably, ion channel activity can be modulated by several synthetic compounds or natural products, leading to a great variety of pharmacological options to regulate their function, reducing tumor progression, as has also been proven by pre-clinical mouse model in vivo.

In this Special Issue, we welcome reviews, new methods, and original articles covering any aspect of the targeting of ion channels, both plasma membrane and intracellular ones, in cancer. These include, but are not limited to, new drugs discovered to be able to reduce tumor development and progression, new possible ways to modulate ion channels activity, discussion of the state of the art in order to clearly define the future perspectives of the field.

We look forward to your contributions.

Prof. Luigi Leanza
Dr. Vanessa Checchetto
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Ion channels
  • Intracellular organelles
  • Cancer
  • Gene modulation
  • Genetic diseases

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 2062 KiB  
Article
Eag1 Gene and Protein Expression in Human Retinoblastoma Tumors and its Regulation by pRb in HeLa Cells
by María de Guadalupe Chávez-López, Violeta Zúñiga-García, Blanca Elena Castro-Magdonel, Eunice Vera, Efraín Garrido, Janet Sánchez-Ramos, M. Verónica Ponce-Castañeda, M. de Lourdes Cabrera-Muñoz, Yesenia Escobar, Cindy Sharon Ortiz, Elisabeth Hernández-Gallegos, Arturo Avalos-Fuentes and Javier Camacho
Genes 2020, 11(2), 119; https://doi.org/10.3390/genes11020119 - 21 Jan 2020
Cited by 10 | Viewed by 2708
Abstract
Retinoblastoma is the most common pediatric intraocular malignant tumor. Unfortunately, low cure rates and low life expectancy are observed in low-income countries. Thus, alternative therapies are needed for patients who do not respond to current treatments or those with advanced cases of the [...] Read more.
Retinoblastoma is the most common pediatric intraocular malignant tumor. Unfortunately, low cure rates and low life expectancy are observed in low-income countries. Thus, alternative therapies are needed for patients who do not respond to current treatments or those with advanced cases of the disease. Ether à-go-go-1 (Eag1) is a voltage-gated potassium channel involved in cancer. Eag1 expression is upregulated by the human papilloma virus (HPV) oncogene E7, suggesting that retinoblastoma protein (pRb) may regulate Eag1. Astemizole is an antihistamine that is suggested to be repurposed for cancer treatment; it targets proteins implicated in cancer, including histamine receptors, ATP binding cassette transporters, and Eag channels. Here, we investigated Eag1 regulation using pRb and Eag1 expression in human retinoblastoma. The effect of astemizole on the cell proliferation of primary human retinoblastoma cultures was also studied. HeLa cervical cancer cells (HPV-positive and expressing Eag1) were transfected with RB1. Eag1 mRNA expression was studied using qPCR, and protein expression was assessed using western blotting and immunochemistry. Cell proliferation was evaluated with an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. RB1 transfection down-regulated Eag1 mRNA and protein expression. The human retinoblastoma samples displayed heterogeneous Eag1 mRNA and protein expression. Astemizole decreased cell proliferation in primary retinoblastoma cultures. Our results suggest that Eag1 mRNA and protein expression was regulated by pRb in vitro, and that human retinoblastoma tissues had heterogeneous Eag1 mRNA and protein expression. Furthermore, our results propose that the multitarget drug astemizole may have clinical relevance in patients with retinoblastoma, for instance, in those who do not respond to current treatments. Full article
(This article belongs to the Special Issue Role of Ion Channel Genes as Targets in Oncology)
Show Figures

Figure 1

Back to TopTop